Liminatus Pharma Regains Compliance with Nasdaq Listing Requirements

Key Facts

1Liminatus Pharma announced it has regained compliance with Nasdaq's continued listing requirements.

Liminatus Pharma announced it has regained compliance with Nasdaq's continued listing requirements. Seeking Alpha reported that the company resolved previous deficiencies that threatened its listing status, officially meeting the necessary regulatory thresholds to maintain its position on the exchange.

LIMN closed at $4.27 on September 28, 2026, with the stock reaching a day high of $4.48 and a low of $4.13 during that session. This milestone removes the immediate threat of delisting and is expected to stabilize investor confidence in the micro-cap firm's market standing.